Several EGFR-TKIs are commercially available in clinical practice, including first-generation gefitinib, erlotinib, and icotinib, second-generation dacomitinib and afatinib, and third-generation osimertinib and almonertinib, which has been investigated in early-stage NSCLC patients harboring EGFR mutation. This evidence concerns the gene EGFR and non-small cell lung carcinoma.